Medicinova (MNOV) Stock: Buy, Sell, or Hold?
MNOV - Medicinova, Inc.
$1.81
0.07 (4.02%)
▲
5d:
+11.73%
30d:
+36.09%
90d:
+41.41%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When MNOV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: MNOV is 15.3% above its trading range ($1.57). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: MNOV is 15.3% above its trading range ($1.57). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: MNOV is currently trading at $1.81, which is considered extended relative to its 30-day fair value range of $1.29 to $1.57.
Technical Outlook: Technically, MNOV is in a uptrend. The price is approaching resistance at $1.85. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: MNOV scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.00 (+397.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MNOV is in a uptrend. The price is approaching resistance at $1.85. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: MNOV scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.00 (+397.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.29 -
$1.57
Company Quality Score
31/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price significantly overextended (+15.3% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.0%)
- BULLISH: Trading 397.2% below Wall St target ($9.00)
- WARNING: Composite score 31/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.29 -
$1.57
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.42
Resistance Level
$1.85
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.02
Wall Street Target
$9.00
(+397.2%)
Revenue Growth (YoY)
240.6%
Share & Embed Analysis
Last updated: September 13, 2026 6:32 PM ET
Data refreshes hourly during market hours. Next update: 7:32 PM
Data refreshes hourly during market hours. Next update: 7:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MNOV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 50 HOLD |
|
JSPR
Jasper Therapeutics Inc |
STRONG BUY
11 analysts |
$7 | 62 BUY |
|
RLAY
Relay Therapeutics Inc |
STRONG BUY
13 analysts |
$27 | 64 BUY |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$37 | 44 HOLD |
